The Extraordinary General Meeting of the Arab Company for Drug Industries & Medical Appliances (SAIPH), held on December 20, 2021 in Tunis, decided on a 2nd capital increase of 30 million dinars.
This increase is in addition to the one decided by the Extraordinary General Assembly of June 15, 2021, in the amount of 4.5 million dinars, to reach a total increase of the company’s capital of 34.5 million dinars for 2021.
This increase in which Tunisian partner banks participated, namely Amen Bank Group (up to 14.21%) and the “Banque de Tunisie” (up to 1.16%), aims to finance the development plan already undertaken by SAIPH, in Tunisia and in Africa and to enable it to seize growth opportunities, both locally and internationally.
SAIPH has made investments of more than 60 million dinars over the last four years, with the aim of increasing its production capacity and introducing other innovative galenic forms.
The SAIPH Group is one of the largest Tunisian Pharmaceutical Laboratories and a global and diversified health player. It is the leading manufacturer of cardiovascular drugs and antibiotics in Tunisia. It also manufactures a wide range of medicines treating the main pathologies present in Tunisia and Africa.
SAIPH also produces a wide range of medicines for the treatment of the most common diseases.
SAIPH also achieved the best growth in the Tunisian pharmaceutical market: +90% in four years.
It employs more than 700 people in Tunisia for its industrial and medical information and promotion activities.
To boost its activities in Africa, SAIPH has set up a pharmaceutical factory and a drug promotion and distribution agency in Abidjan, Côte d’Ivoire, creating a second platform for all of sub-Saharan Africa.
